Literature DB >> 65282

Intravascular persistence of hydroxyethyl starch in man.

J C Boon, F Jesch, J Ring, K Messmer.   

Abstract

In two groups, each consisting of five healthy volunteers, 7 ml blood/kg body weight were exchanged with equal amount of hydroxyethyl starch (HES) and dextran 60 solutions, respectively. Dextran 60 plasma levels, determined by the anthrone method, were undetectable after 4 weeks. The elimination of HES from the blood, determined by an immunological technique and by the anthrone method, had a very protracted course. Two weeks after infusion the HES plasma concentrations were 9% of the initial value and after 17 weeks they were still above the 1% level. The prolonged intravascular persistence of HES in its commercially available preparation, and the possibility of tissue accumulation after repeated HES infusions were considered undesirable. The hypothesis that HES infusion causes and augmentation of serum alpha-amylase concentrations in man was confirmed. This effect should be borne in mind when HES solutions are given to patients in whom the diagnosis of acute pancreatitis might be considered.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 65282     DOI: 10.1159/000127896

Source DB:  PubMed          Journal:  Eur Surg Res        ISSN: 0014-312X            Impact factor:   1.745


  11 in total

Review 1.  Pharmacokinetics of hydroxyethyl starch.

Authors:  Cornelius Jungheinrich; Thomas A Neff
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 2.  Adverse reactions to plasma volume expanders.

Authors:  M M Fisher; P W Brady
Journal:  Drug Saf       Date:  1990 Mar-Apr       Impact factor: 5.606

Review 3.  The use of plasma substitutes with special attention to their side effects.

Authors:  K F Messmer
Journal:  World J Surg       Date:  1987-02       Impact factor: 3.352

4.  [The elimination of hydroxyethyl starch 200/0.5, dextran 40 and oxypolygelatine (author's transl)].

Authors:  H Köhler; H Zschiedrich; A Linfante; F Appel; H Pitz; R Clasen
Journal:  Klin Wochenschr       Date:  1982-03

5.  Pruritus after administration of hetastarch.

Authors:  N E Parker; J B Porter; H J Williams; N Leftley
Journal:  Br Med J (Clin Res Ed)       Date:  1982-02-06

6.  Mechanisms of postoperative prolonged plasma volume expansion with low molecular weight hydroxethy starch (HES 200/0.62, 6%).

Authors:  A C Degrémont; M Ismaïl; M Arthaud; B Oulare; O Mundler; M Paris; J F Baron
Journal:  Intensive Care Med       Date:  1995-07       Impact factor: 17.440

7.  Urinary excretion kinetics of hydroxyethyl starch 350/0.60 in normovolaemic man.

Authors:  J M Mishler; C R Ricketts; E J Parkhouse
Journal:  J Clin Pathol       Date:  1981-04       Impact factor: 3.411

8.  Changes in the molecular size distribution and post-transfusion survival of hydroxyethyl starch 350/0.60 as influenced by a lower degree of hydroxyethylation: a study in normal man.

Authors:  J M Mishler; C R Ricketts; E J Parkhouse
Journal:  J Clin Pathol       Date:  1980-09       Impact factor: 3.411

9.  Post-transfusion survival of hydroxyethyl starch 450/0.70 in man: a long-term study.

Authors:  J M Mishler; C R Ricketts; E J Parkhouse
Journal:  J Clin Pathol       Date:  1980-02       Impact factor: 3.411

Review 10.  Clinical pharmacokinetic considerations in the use of plasma expanders.

Authors:  U Klotz; H Kroemer
Journal:  Clin Pharmacokinet       Date:  1987-02       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.